Skip to main content
. 2022 May;23(5):1571–1576. doi: 10.31557/APJCP.2022.23.5.1571

Table 1.

Clinicopathological Features of Breast Cancer Cases Evaluated for HPV and p16 Staining

Features Total HPV (n=447) p16 staining (n=238)
Negative Positive P Negative Positive P
n (%) n (%) n (%) n (%) n (%)
Age (year) 0.577 0.456
≤ 51 year 206 (46.5) 201 (97.5) 5 (2.5) 70 (69.3) 31 (30.7)
> 51 year 241 (53.5) 233 (96.6) 8 (3.4) 101 (73.7) 36 (26.3)
Tumor size 0.82 0.022
I 28 (6.2) 28 (100.0) 0 (0.0) 14 (93.3) 1 (6.6)
II 195 (43.6) 189 (96.0)) 6 (4.0) 92 (76.6) 28 (23.4)
III 54 (12.4) 51 (94.4) 3 (5.6) 20 (55.5) 16 (44.5)
IV 160 (35.8) 156 (97.5) 4 (2.5) 44 (68.8) 20 (31.2)
Stage  0.549 0.076
I 17 (4.6) 17 (100.0) 0 (0.0) 8 (80.0) 2 (20.0)
II 146 (45.4) 141 (96.6) 5 (3.4) 99 (76.7) 30 (23.3)
III 225 (36.9) 217 (96.4) 8 57 (65.5) 30 (34.5)
IV 59 (13.1) 59 (100.0) 0 (0.0) 7 (58.3) 5 (41.7)
Grade 0.097 0.009
I 10 (2.5) 10 (100.0) 0 (0.0) 5 (62.5) 3 (37.5)
II 151 (33.9) 143 (95.0) 8 (5.0) 69 (82.2) 13 (17.8)
III 284 (63.3) 279 (98.2) 5 (1.8) 97 (65.5) 51 (34.5)
TIL (%) 0.809 0.002
<30 218 (54.9) 211 (96.8) 7 (3.2) 96 (81.4) 22 (18.6)
≥30 179 (45.1) 174 (97.2) 5 (2.8) 73 (62.9) 43 (37.1)
Histology 0.003 0.145
Ductal 400 (89.5) 392 (98.0) 8 (2.0) 71.8 58 (28.3)
Lobulillar 25 (5.6) 22 (88.0) 3 (12.0) 14 (87.5) 2 (12.5)
Other 22 (4.9) 20 (90.9) 2 (9.1) 9 (56.3) 7 (41.2)
Phenotype 0.181 0.021
Luminal-A 69 (15.7) 65 (15.0) 4 (30.8) 37 (82.2) 8 (17.8)
Luminal-B 236 (53.8) 230 (97.5) 6 (2.5) 95 (71.9) 37 (28.1)
HER-2 66 (15.0) 64 (97.0) 2 (3.0) 20 (80.0) 5 (20)
TNBC 68 (15.5) 67 (98.5) 1 (1.5) 18 (51.4) 17 (48.6)
p16  0.017
Negative 171 (71.8) 166 (97.1) 5 (2.9) -
Positive 67 (28.2) 60 (89.5) 7 (10.5) -

TNBC, triple negative breast cancer; TIL, Tumor Infiltrating Lymphocytes; P.value<0.05